Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics chief business officer Eric Pauwels exercised stock options and sold shares in pre-planned trades. On June 10, 2026, he exercised options to acquire 17,566 shares of Common Stock at $18.01 per share, then executed open-market sales totaling 21,277 shares at $75.00 per share. Following these transactions, he held 73,411 shares of Common Stock directly. The trades were carried out under a written Rule 10b5-1 plan adopted on February 25, 2026, indicating they were pre-scheduled rather than timed discretionarily.
PTCT affiliate submitted a Form 144 notice to sell securities on 06/10/2026. The filing lists 17,566 shares tied to a Stock Option Exercise and 3,711 shares tied to Restricted Stock Vesting, with a broker listed as Fidelity Brokerage Services LLC.
PTC Therapeutics reports that board member Alethia Young resigned from its board of directors effective June 8, 2026. She stated that the decision reflects the need to focus on other work commitments and was not due to any disagreement with the company.
On the same date, Young entered into a Consulting Agreement under which she will continue as an advisor to PTC Therapeutics through June 8, 2027. For these advisory services, she will receive a monthly consulting fee of $4,166.67, as detailed in Exhibit 10.1 to the report.
PTC Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 2, 2026. As of the April 10, 2026 record date, 82,911,783 common shares were outstanding, with each share entitled to one vote.
Stockholders elected four Class I directors to serve until the 2029 annual meeting: Jessica Chutter, Matthew B. Klein, M.D., M.S., F.A.C.S., Stephanie S. Okey, M.S., and Jerome B. Zeldis, M.D., Ph.D., each receiving over 68.9 million votes “For.”
Ernst & Young LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026, with 76,170,292 votes “For.” A non-binding advisory vote on named executive officer compensation was also approved, receiving 71,166,204 votes “For.”
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and CLO, exercised stock options for 2,812 shares of Common Stock at $25.69 per share and, on the same date, sold 2,812 shares in open-market transactions at weighted average prices of $72.67 and $72.08. These trades were made under a pre-arranged Rule 10b5-1 plan. Following the transactions, he directly holds 105,212 Common Stock shares and 19,689 stock options.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported a mix of equity compensation and related tax sales. On May 13, 2026, he acquired 12,500 shares of common stock through earned performance-based RSUs after a pre-established milestone was certified.
Of these earned RSUs, 6,250 shares vested immediately on May 13, 2026 and another 6,250 shares are scheduled to vest on May 13, 2027. On May 14, 2026, a total of 12,572 shares of common stock were sold in open-market transactions solely to satisfy tax withholding obligations under an irrevocable sell-to-cover election. Following these transactions, Klein directly owned 393,998 shares of PTC Therapeutics common stock.
PTC Therapeutics ownership update: The Toronto-Dominion Bank reports beneficial ownership of 3,025,945 shares of common stock, representing 3.7% of the class. The filing is an Amendment No. 1 to a Schedule 13G/A and is signed on 05/15/2026.
The statement lists sole voting and sole dispositive power over the same 3,025,945 shares. The filing notes ownership is 5% or less of the class.
Janus Henderson Group plc reports beneficial ownership of 7,193,433 shares of PTC Therapeutics, Inc. as of 03/31/2026 This represents 8.7% of the company's common stock. The filing states the Asset Managers exercise shared voting and shared dispositive power over these shares and disclaim rights to receive dividends or sale proceeds on behalf of the managed accounts. The report clarifies the holdings are held across multiple Janus Henderson asset management entities acting for client-managed portfolios.
Filer submitted a Form 144 notifying the sale of Common stock. The notice lists 2,812 shares identified for sale on 05/15/2026 and shows prior reported sales by Mark Boulding of 2,265 shares on 04/06/2026 and 3,540 shares on 05/08/2026. The filing records cash settlement methods.
PTCT reported Form 144 transactions showing sales of Common stock by Matthew Klein and a restricted stock vesting. The filing lists three sales by Matthew Klein: 7,371 shares on 02/18/2026 for $511,227.50, 2,662 shares on 03/12/2026 for $170,572.44, and 2,850 shares on 04/21/2026 for $202,171.31. The excerpt also shows 2,572 shares vested as restricted stock on 05/13/2026 reported as compensation.